TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28438144

Group type: EXPERIMENTAL
Intervention: App-based HIV prevention intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care (HIV/STDs knowledge brochure and free voluntary counseling services)
Number of subjects: 800
Study: 24915562

Group type: EXPERIMENTAL
Intervention: S. boulardii 125 mg every 12 hours during phototherapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo during phototherapy
Number of subjects: 119
Study: 23793409

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Interferon β 1a
Number of subjects: 2
Study: 22336311

Group type: EXPERIMENTAL
Intervention: Low dose pituitrin (0.01 - 0.03 U/min) added to conventional treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional treatment (antibiotics, fluid resuscitation, glucocorticoids, organ support, dopamine 1-15 µg/(kg·min), norepinephrine 0.5-2 µg/(kg·min))
Number of subjects: 48
Study: 18795367

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 13
Study: 16918520

Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11135022

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9023463

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation during summer
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 900
Study: 8389181

Group type: EXPERIMENTAL
Intervention: Chemoembolization (CE) with doxorubicin and Gelfoam with or without Lipiodol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Chemoembolization (CE) with doxorubicin and Gelfoam
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Chemoembolization (CE) with cis-platinum, Lipiodol, and Gelfoam
Number of subjects: 232
Study: 2446055

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 13
Study: 29413063

Group type: EXPERIMENTAL
Intervention: Nurse led self-management intervention
Number of subjects: 10
Study: 27886247

Group type: EXPERIMENTAL
Intervention: Acupuncture (AG, n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moxibustion (MG, n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG, n=15)
Number of subjects: 45
Study: 24107427

Group type: EXPERIMENTAL
Intervention: Lumbopelvic belts
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 22100560

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxic challenge (P(ET)O(2) of 500 mm Hg with P(ET)CO(2) maintained at 38 mm Hg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxic challenge
Number of subjects: 17
Study: 19755414

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (4 days)
Number of subjects: 11
Study: 19162756

Group type: EXPERIMENTAL
Intervention: Isothermic hemodiafiltration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thermoneutral hemodiafiltration
Number of subjects: 12
Study: 16958712

Group type: EXPERIMENTAL
Intervention: Interactive therapeutic nurse-client relationships
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maternal/social role preparation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Formal teaching
Number of subjects: 28

Group type: COMPARATOR
Intervention: Instructions without nurse input
Number of subjects: 28
Study: 14646761

Group type: EXPERIMENTAL
Intervention: Oxidized Zr femoral component
Number of subjects: 0

Group type: COMPARATOR
Intervention: CoCrMo femoral component
Number of subjects: 0
Study: 12515132

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (once, 48 hours before operation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (twice, 96 hours and 48 hours before operation)
Number of subjects: 30
Study: 10832472

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg IVIG on the first day of life
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no IVIG)
Number of subjects: 76
Study: 8180536

Group type: EXPERIMENTAL
Intervention: Case management for 56 patients admitted to three hospitals
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard rehabilitation services
Number of subjects: 126
Study: 3371858

Group type: EXPERIMENTAL
Intervention: Betamethasone (6.0 mg for the first 5 days, 4.5 mg for the following week, and then 3.0 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29499504

Group type: EXPERIMENTAL
Intervention: Internet-delivered DBT skills training (iDBT-ST)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 59
Study: 27039954

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Naloxone (opioid blocker)
Number of subjects: 15
Study: 26349124

Group type: EXPERIMENTAL
Intervention: Oral-B Pulsar manual brush (OBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate Whitening manual brush (CW)
Number of subjects: 0
Study: 23590986

Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy and 3 courses of FOLFOX4 (schedule I)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 50.4 Gy delivered in 28 fractions with 5‐Fu, leucovorin and oxaliplatin (schedule II)
Number of subjects: 97
Study: 21664512

Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg daily for three cycles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg every other day for three cycles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control cycles (not explicitly defined in the abstract)
Number of subjects: 10
Study: 18294410

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 100 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intraperitoneal tramadol 100 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 61
Study: 16216400

Group type: EXPERIMENTAL
Intervention: Mild positive affect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral affect
Number of subjects: 0
Study: 12700448

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 298
Study: 11121720

Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 or 6 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diets (0.7/1.6/6.0 mg/d)
Number of subjects: 0
Study: 8594164

Group type: EXPERIMENTAL
Intervention: Short-term drug abuse treatment (23-day duration)
Number of subjects: 0
Study: 1695312

Group type: EXPERIMENTAL
Intervention: Isradipine (7.5 mg b.i.d.)
Number of subjects: 17
Study: 293493

Group type: EXPERIMENTAL
Intervention: Continuing therapy for a total of six years
Number of subjects: 83

Group type: COMPARATOR
Intervention: Stopping therapy after three years
Number of subjects: 83
Study: 31349945

Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CoQ10 plus Vitamin E
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CoQ10 and Vitamin E (alone or in combination)
Number of subjects: 86
Study: 28181728

Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16492
Study: 25458262

Group type: EXPERIMENTAL
Intervention: Allogeneic transplant (34 patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Autologous transplant (31 patients)
Number of subjects: 65
Study: 24246597

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 2 hours daily between days of life 5 to 10
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard incubator care
Number of subjects: 38
Study: 20955771

Group type: EXPERIMENTAL
Intervention: Rauvolfia-Citrus tea
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 19349317

Group type: EXPERIMENTAL
Intervention: Intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HDL and apolipoprotein AI
Number of subjects: 13
Study: 16426899

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 14988449

Group type: EXPERIMENTAL
Intervention: Soy protein depleted of isoflavones
Number of subjects: 36

Group type: COMPARATOR
Intervention: Animal protein with no added isoflavones
Number of subjects: 36

Group type: COMPARATOR
Intervention: Animal protein with added isoflavones
Number of subjects: 36
Study: 11706339

Group type: EXPERIMENTAL
Intervention: Standard radiographs of the fractured and normal wrists
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard radiographs of the uninjured wrist
Number of subjects: 38
Study: 9322632

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microgram tablets every 4 hours for a maximum of six doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dinoprostone (10 mg vaginal insert for a maximum of 24 hours)
Number of subjects: 200
Study: 7993573

Group type: EXPERIMENTAL
Intervention: High-dose OKT3 (5 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low-dose OKT3 (2 mg)
Number of subjects: 26
Study: 3054035

Group type: EXPERIMENTAL
Intervention: Nalidixic acid (55 mg/kg/day for 5 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ampicillin (100 mg/kg/day for 5 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ampicillin-resistant group (ampicillin-R)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nalidixic acid
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nalidixic acid and Ampicillin
Number of subjects: 68
Study: 30877049

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Attention Control Training (ACT)
Number of subjects: 64
Study: 31216900

Group type: EXPERIMENTAL
Intervention: RCT intervention (details not specified)
Number of subjects: 2
Study: 28096757

Group type: EXPERIMENTAL
Intervention: PWS (pre-workout dietary supplement)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PWS + S (pre-workout dietary supplement with synephrine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PLA (flavored placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PWS and PWS + S
Number of subjects: 80
Study: 25925713

Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Standard care and rehabilitation
Number of subjects: 880
Study: 22476876

Group type: EXPERIMENTAL
Intervention: High-flavonoid diet (HF)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Low-flavonoid diet (LF)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 174
Study: 21676480

Group type: EXPERIMENTAL
Intervention: HbA1c of 5.7%
Number of subjects: 9723

Group type: EXPERIMENTAL
Intervention: HbA1c range of 5.7-6.4%
Number of subjects: 9723
Study: 19935022

Group type: EXPERIMENTAL
Intervention: Paracervical block with combined ketorolac and lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paracervical block with lidocaine alone
Number of subjects: 50
Study: 16797309

Group type: EXPERIMENTAL
Intervention: Vardenafil treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group without ED
Number of subjects: 39
Study: 12587810

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist comanagement (PPCM)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study: 11023085

Group type: EXPERIMENTAL
Intervention: BCAA 150 g daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standardized diet with 80 g protein daily
Number of subjects: 29
Study: 9407258

Group type: EXPERIMENTAL
Intervention: Gamma-oryzanol supplementation (500 mg.day-1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 50
Study: 1316722

Group type: EXPERIMENTAL
Intervention: Treatwell work-site nutrition intervention program (direct education and environmental programming)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study: 3918190

Group type: EXPERIMENTAL
Intervention: Oral penicillin for 72 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 44
Study: 30252895

Group type: EXPERIMENTAL
Intervention: Active transcranial pulsed electromagnetic field treatment (squared bipolar 3 ms pulses, 50 Hz) for 30 min/day for 8 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment for 30 min/day for 8 weeks
Number of subjects: 97
Study: 27209465

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg sc bid
Number of subjects: 162
Study: 25414932

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/d
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Saxagliptin + insulin +/‐ metformin
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1961
Study: 21675122

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells transplantation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no cells transplantation)
Number of subjects: 27
Study: 19218179

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 851

Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 851
Study: 17978322

Group type: EXPERIMENTAL
Intervention: DIALOG intervention
Number of subjects: 507

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 507
Study: 15130080

Group type: EXPERIMENTAL
Intervention: Oral Balance gel (used three times a day for 90 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: gel placebo (used three times a day for 90 days)
Number of subjects: 21
Study: 11328911

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 135

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 135
Study: 9164361

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms once daily for 4 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 8431629

Group type: EXPERIMENTAL
Intervention: Hourly pain assessments for 48 hours using VAS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 48-hour recall of worst pain
Number of subjects: 84
Study: 2959626

Group type: EXPERIMENTAL
Intervention: Antitissue immunoglobulins (Sérocytol Neuro‐Vasculaire) administered by intradermal injections
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 362293

Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy (1 mg Corynebacterium parvum i.v. on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy (MeCCNU, 200 mg/m2, given orally every 8 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy (C. parvum + MeCCNU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy (MeCCNU)
Number of subjects: 34
Study: 31742881

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259
Study: 31134272

Group type: EXPERIMENTAL
Intervention: Flock weight uniformity (CV of BW)
Number of subjects: 45
Study: 28345792

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with faster aspart (n=116)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Basal-only insulin (n=120)
Number of subjects: 236
Study: 25771851

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23741880

Group type: EXPERIMENTAL
Intervention: BCG-MOSCOW (3-33 x 10(5) cells), injected intra-dermally at 3 month intervals (Gr A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Normal saline (0.85%), injected intra-dermally at 3 month intervals (Gr B)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: BCG-MOSCOW (Gr A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Normal saline (Gr B)
Number of subjects: 107
Study: 22152769

Group type: EXPERIMENTAL
Intervention: Bufei Yishen Granule combined with acupoint‐sticking therapy
Number of subjects: 244

Group type: COMPARATOR
Intervention: Sustained‐release theophylline (control)
Number of subjects: 244
Study: 19095990

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Nonspecific ST- and T-wave abnormalities
Number of subjects: 588
Study: 17185398

Group type: EXPERIMENTAL
Intervention: Stress-reducing decorated butterfly needles and syringes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional needles and syringes
Number of subjects: 50
Study: 15061044

Group type: EXPERIMENTAL
Intervention: Low level laser irradiation (LLLI), 10 sessions
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Thermographic response to cold challenge
Number of subjects: 47
Study: 11506061

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High iron diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Iron replete women (control group)
Number of subjects: 44
Study: 9625090

Group type: EXPERIMENTAL
Intervention: 600-mL preload
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300-mL preload
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 450-mL preload
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (no drink)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 20
Study: 7941664

Group type: EXPERIMENTAL
Intervention: High work rate cycle ergometer training for 45 min/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low work rate cycle ergometer training for a proportionally longer time
Number of subjects: 19
Study: 3356742

Group type: EXPERIMENTAL
Intervention: Cleaning with 70% isopropyl alcohol prior to catheter removal (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cleaning prior to catheter removal (Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Blood cultures
Number of subjects: 50
Study: 30442165

Group type: EXPERIMENTAL
Intervention: Facilitation intervention
Number of subjects: 746
Study: 28086851

Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-Hz high-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 60
Study: 26316562

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 13
Study: 23724875

Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 10
Study: 21036173

Group type: EXPERIMENTAL
Intervention: PEG alfa-2a (PEG-2a; 180 μg/1.73 m(2) body surface area, subcutaneously each week) and ribavirin (15 mg/kg orally in 2 doses daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: PEG alfa-2a (PEG-2a) and placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: PEG alfa-2a (PEG-2a) and ribavirin
Number of subjects: 114
Study: 18460701

Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil 16 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 16895883

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) breakfast
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) breakfast
Number of subjects: 8
Study: 15252294

Group type: EXPERIMENTAL
Intervention: Acamprosate (0, 2, and 4 g, p.o.)
Number of subjects: 0
Study: 11333096

Group type: EXPERIMENTAL
Intervention: 4 mL fibrin sealant at axillary dissection site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16 mL fibrin sealant at axillary dissection site and 8 mL at skin flap site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no agent)
Number of subjects: 0
Study: 9052310

Group type: EXPERIMENTAL
Intervention: Augustine Scope (AS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 200
Study: 8136395

Group type: EXPERIMENTAL
Intervention: Scopolamine and ketorolac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine and morphine
Number of subjects: 0
Study: 3027153

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg from a metered-dose inhaler
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium, 20 mg from a Spinhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31978225

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by maintenance lenalidomide
Number of subjects: 301

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by placebo
Number of subjects: 301
Study: 28954826

Group type: EXPERIMENTAL
Intervention: CR+F (standard CR with additional face-to-face active lifestyle counselling and group fitness training)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: CR+T (standard CR extended with telephone lifestyle counselling)
Number of subjects: 914

Group type: COMPARATOR
Intervention: CR-only (standard CR)
Number of subjects: 914